<DOC>
	<DOCNO>NCT02712671</DOCNO>
	<brief_summary>Human Immunodeficiency Virus ( HIV ) strong individual risk factor reactivation tuberculosis ( TB ) previous exposure Mycobacterium tuberculosis ( MTb ) . This risk reduce completely eliminate HIV treat antiretroviral therapy ( ART ) . Both British HIV Association ( BHIVA ) National Institute Health Care Excellence ( NICE ) suggest test latent TB infection HIV infected individual , use different criterion . The cost -effectiveness either approach assess , test widespread . A certain proportion HIV infect subject Africa MTb detectable sputum despite symptom ( cough weight loss ) , change chest x ray . It unclear happen low TB prevalence area United Kingdom ( UK ) . We intend test cohort HIV infect subject evidence latent TB use tuberculin skin test ( TST ) Interferon Gamma Release Assay ( IGRA ) , ask symptom ( use standardise questionnaire ) induce sputum use saline nebuliser , detect MTb use microscopy culture , new nucleic acid amplification ( genetic ) technique . Some patient , despite expose TB past , mount response use IGRA TST , maybe due abnormal immune response . This lack response seem common HIV . By investigate number patient positive TST , IGRA , chest X ray evidence MTb sputum , context place birth , previous exposure TB , CD4 count medication , assess cost- effectiveness systematic TB screening use anti-TB antibiotic prevent reactivation TB . In time , able answer important question time take reactivate TB individual HIV n't take preventative anti-TB medication UK .</brief_summary>
	<brief_title>Testing Tuberculosis United Kingdom HIV Infected Population</brief_title>
	<detailed_description>The investigator would like assess cohort human immunodeficiency virus ( HIV ) infect individual Ian Charleson Centre , Royal Free Hospital ass rate latent tuberculosis infection ( LTBI ) use tuberculin skin test ( TST ) interferon gamma release assay ( IGRA ) , systematically investigate active tuberculosis ( TB ) symptom questionnaire chest X ray , test Mycobacterium tuberculosis ( MTb ) sputum , cough spontaneously possible induce sputum use saline nebuliser test use microscopy culture ( establish method detect MTb ) , nucleic acid amplification test ( use Xpert.TB , new genetic test TB decrease time required detection ) novel 16S ribosomal ribonucleic acid ( RNA ) test , use look TB burden . A cohort people HIV infection invite take part study . Subjects vary place origin , TB exposure risk , blood cluster differentiation 4 ( CD4 ) cell count , HIV viral load , exposure antiretroviral drug use treat HIV . All patient new diagnosis HIV invite , group subject already undergo HIV care ( select stratify sample ) order recruit 180 subject originate sub-Saharan African country 120 low TB incidence country ( United Kingdom , UK Western Europe ) . The study power detect difference form TB infection subject sub-Saharan Africa UK ( low TB prevalence country ) 80 % power , allow 5 % type I error . The participant recruit questionnaire , X ray , sputum induction , TST IGRA take one visit . They need return 48 -- 72 hour later TST read arm . Those evidence LTBI ( positive TST IGRA ) invite TB/HIV clinic quality life score record part study . Research Questions : 1 . To determine feasibility , yield cost -- effectiveness test M. tuberculosis infection UK HIV infected individual . 2 . To determine prevalence subclinical active TB UK HIV infect clinic 3 . To determine sensitivity specificity systematic screening questionnaire detect case active TB outside high TB prevalence setting 4 . To determine concordance TST blood IGRA ( T-Spot.TB ) latent TB infection 5 . To identify risk factor latent TB infection clinic population 6 . To determine underlying frequency airway disease ( use spirometry ) respiratory symptom 7 . To determine sensitivity specificity 'Xpert MTB/RIF ' polymerase chain reaction ( PCR ) test sputum induce sputum compare mycobacterial microscopy culture 8 . To compare Molecular Bacterial Load ( MBL ) assay , base 16S rRNA , available molecular assay , Xpert MTB/RIF detection Mtb 9 . To determine quality life score ( EQ-5D ) HIV infection , without latent TB infection and/or undergo treatment On evidence LTBI : 10 . To determine uptake latent TB therapy ( 6 month isoniazid treatment ) 11 . To determine cost latent TB treatment ( include screening cost , clinic time ) 12 . To determine quality life rate severity adverse event latent TB treatment 13 . To determine rate time active TB LTBI antiretroviral therapy ( ART ) and/or isoniazid prophylaxis In patient ( 20 year follow ) : 14 . To determine rate incident active TB 15 . To determine time progression active TB patient abnormal radiographic change consistent old tuberculosis exposure disease Data generate Research team University College London ( UCL ) Statistics team .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Latent Tuberculosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>New diagnosis HIV establish care HIV clinic stratify sample Able give inform consent Diagnosis active TB undergoing treatment active latent TB Inability produce sputum coughing ( e.g . recent rib fracture , chest pain , pneumothorax ) Pregnancy Use steroid ( equivalent 15mg prednisolone â‰¥4 week ) immunosuppressive drug ( e.g . azathioprine ) relative Active solid organ haematological malignancy ( exclude Kaposi 's sarcoma ) Previous hypersensitivity purify protein derivative ( PPD ) Extensive eczema</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Cost-Benefit Analysis</keyword>
	<keyword>Quality Life</keyword>
</DOC>